In this real-life study of type 2 diabetes patients initiating a GLP-1 RA, longer duration of GLP-1 RA treatment was associated to a lower rate of a composite of non-fatal myocardial infarction or unstable angina, non-fatal stroke, and all-cause death in both primary and secondary prevention. The gene discussed is GCG; the disease is myocardial infarction.